Peter Evan Harwin - 04 Jun 2025 Form 4 Insider Report for Cogent Biosciences, Inc. (COGT)

Reporting relationship: Director
Issuer ticker: COGT
Reported as of: 04 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jun 2025, 16:19:21 UTC
Prior SEC filing: 28 Jun 2024
Next SEC filing: 11 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Evan D. Kearns, Attorney-in-Fact

Key filing fact

Peter Evan Harwin filed Form 4 for Cogent Biosciences, Inc. (COGT) on 05 Jun 2025.

Key facts

This page summarizes Peter Evan Harwin's Form 4 filing for Cogent Biosciences, Inc. (COGT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Jun 2025, 16:19.

Change

Previous filing in this sequence was filed on 28 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001663607 Primary reporting owner

Harwin Peter Evan

Relationship: Director
Address: C/O COGENT BIOSCIENCES, INC., 275 WYMAN STREET, 3RD FLOOR, WALTHAM
Signature: /s/ Evan D. Kearns, Attorney-in-Fact
Signature date: 05 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

COGT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +44,700
Change %
Price: $0.000000
Shares after: 44,700
Date: 04 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 44,700
Exercise price: $5.64
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2026 Annual Meeting of Stockholders.

Footnote F2

Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.